This short matriglycan likely attenuates muscular dystrophy in patient NH13-284 with a complete loss-of-function mutation in POMK, preventing the severe WWS phenotype that is observed in the complete absence of the other known dystroglycanopathy genes. Here, POMK is linked to neuromuscular disease caused by qualitative or quantitative defects of alpha-dystroglycan.